Losartan vs Candesartan
Overview
Candesartan cilexetil (prodrug → candesartan) and losartan are both ARBs but candesartan has particularly strong evidence in heart failure and is considered one of the most potent ARBs in terms of AT1 receptor affinity.
Mechanism of Action
Both block AT1. Candesartan has the highest AT1 receptor affinity among ARBs and shows very slow dissociation (insurmountable binding), providing prolonged receptor blockade. Losartan is surmountable.
Pharmacokinetics
Candesartan cilexetil: prodrug hydrolyzed to candesartan during GI absorption, bioavailability ~42%, half-life ~9 h, biliary/renal elimination, not significantly metabolized by CYP. Losartan: prodrug converted to E-3174 by CYP2C9.
Clinical Evidence
CHARM program (candesartan) is notable: CHARM-Alternative showed candesartan reduced CV death and HF hospitalizations in ACEi-intolerant HFrEF patients; CHARM-Added showed benefit when added to ACEi. Losartan's landmark HF trial is ELITE II (vs. captopril in elderly HF — non-inferiority, not superiority).
Key Takeaways
- Candesartan: highest AT1 affinity among ARBs, strong HF evidence (CHARM program)
- Losartan: uricosuric, lower AT1 affinity, surmountable binding
- Candesartan preferred for HFrEF in ACEi-intolerant patients
Fazit
Candesartan is preferred for heart failure patients intolerant to ACE inhibitors based on CHARM program evidence. Losartan is preferred when uric acid lowering is a secondary therapeutic goal. For hypertension without HF, both are comparable first-line ARBs.